



Swansea University
Prifysgol Abertawe



Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in :
New England Journal of Medicine

Cronfa URL for this paper:

<http://cronfa.swan.ac.uk/Record/cronfa30129>

Paper:

Marso, S., Bain, S., Consoli, A., Eliaschewitz, F., Jódar, E., Leiter, L., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M., Woo, V., Hansen, O., Holst, A., Pettersson, J. & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*
<http://dx.doi.org/10.1056/NEJMoa1607141>

This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions. When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO database to judge whether or not it is copyright safe to add this version of the paper to this repository.

<http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/>

ORIGINAL ARTICLE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators*

ABSTRACT

BACKGROUND

Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.

METHODS

We randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks. The primary composite outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. We hypothesized that semaglutide would be noninferior to placebo for the primary outcome. The noninferiority margin was 1.8 for the upper boundary of the 95% confidence interval of the hazard ratio.

RESULTS

At baseline, 2735 of the patients (83.0%) had established cardiovascular disease, chronic kidney disease, or both. The primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and in 146 of 1649 patients (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95; $P < 0.001$ for noninferiority). Nonfatal myocardial infarction occurred in 2.9% of the patients receiving semaglutide and in 3.9% of those receiving placebo (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; $P = 0.12$); nonfatal stroke occurred in 1.6% and 2.7%, respectively (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; $P = 0.04$). Rates of death from cardiovascular causes were similar in the two groups. Rates of new or worsening nephropathy were lower in the semaglutide group, but rates of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) were significantly higher (hazard ratio, 1.76; 95% CI, 1.11 to 2.78; $P = 0.02$). Fewer serious adverse events occurred in the semaglutide group, although more patients discontinued treatment because of adverse events, mainly gastrointestinal.

CONCLUSIONS

In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide. (Funded by Novo Nordisk; SUSTAIN-6 ClinicalTrials.gov number, NCT01720446.)

From the Research Medical Center, Kansas City, MO (S.P.M.); School of Medicine, Swansea University, Swansea, United Kingdom (S.C.B.); Department of Medicine and Aging Science and Center of Excellence on Aging and Translational Medicine, G. d'Annunzio University, Chieti-Pescara, Italy (A.C.); CPclin Research Center/Hospital Israelita Albert Einstein, São Paulo (F.G.E.); Hospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid (E.J.); Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.), and the University of Manitoba, Winnipeg (V.W.) — both in Canada; University of Texas Southwestern Medical Center (I.L.) and Dallas Diabetes Research Center at Medical City (J.R.) — both in Dallas; University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany (J.S.); Physicians East, Greenville, NC (M.L.W.); and Novo Nordisk, Søborg (O.H., A.G.H., J.P.), and the Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup (T.V.) — both in Denmark. Address reprint requests to Dr. Marso at Cardiovascular Services, HCA Midwest Health, Research Medical Center, 2316 E. Meyer Blvd., Kansas City, MO 64132, or at smarso@gmail.com.

*A complete list of the investigators in the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on September 16, 2016, at NEJM.org.

N Engl J Med 2016;375:1834-44.

DOI: 10.1056/NEJMoa1607141

Copyright © 2016 Massachusetts Medical Society.

CARDIOVASCULAR DISEASE IS THE LEADING cause of death and complications in patients with type 2 diabetes.¹ Recently, trials evaluating a sodium–glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes in patients with type 2 diabetes who were at high risk for cardiovascular events.^{2,3}

Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration),⁴ is currently in development but not yet approved for the treatment of type 2 diabetes. Regulatory guidance specifies the need to establish the cardiovascular safety of new therapies for type 2 diabetes in order to rule out excess cardiovascular risk.⁵ The preapproval Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) was designed to assess the noninferiority of semaglutide as compared with placebo in terms of cardiovascular safety in patients with type 2 diabetes.

METHODS

TRIAL DESIGN AND OVERSIGHT

We performed a randomized, double-blind, placebo-controlled, parallel-group trial at 230 sites in 20 countries. The trial protocol, available with the full text of this article at NEJM.org, was approved by the institutional review board and ethics committee at each participating center. All patients provided written informed consent.

Patients were randomized in a 1:1:1 ratio to receive either 0.5 mg or 1.0 mg of once-weekly subcutaneous semaglutide or volume-matched placebo, which maintained blinding within dose. The trial consisted of a planned observation period of 109 weeks for all patients (a 104-week treatment period with a 5-week follow-up period) in which patients who had prematurely discontinued a study treatment were also included.

The sponsor, Novo Nordisk, designed the study. Data were gathered by the site investigators, and the sponsor performed site monitoring, data collection, and data analysis. An independent data and safety monitoring committee performed ongoing surveillance and had access to all the data in an unblinded fashion.

All the authors had confidential access to the final trial results and actively contributed to

manuscript preparation. A working group that included the first and last authors wrote the first draft of the manuscript, which was revised and approved by all the authors, who made the decision to submit the manuscript for publication. The authors assume responsibility for the accuracy and completeness of the data and vouch for the fidelity of the trial to the protocol. Editorial support was funded by the sponsor and provided by independent medical writers under the guidance of the authors.

PATIENTS

Patients with type 2 diabetes and a glycated hemoglobin level of 7% or more were eligible if they had not been treated with an antihyperglycemic drug or had been treated with no more than two oral antihyperglycemic agents, with or without basal or premixed insulin. Key inclusion criteria were an age of 50 years or more with established cardiovascular disease (previous cardiovascular, cerebrovascular, or peripheral vascular disease), chronic heart failure (New York Heart Association class II or III), or chronic kidney disease of stage 3 or higher or an age of 60 years or more with at least one cardiovascular risk factor (as defined in Table S1 in the Supplementary Appendix, available at NEJM.org).

Key exclusion criteria included treatment with a dipeptidyl-peptidase 4 inhibitor within 30 days before screening or with a GLP-1-receptor agonist or insulin other than basal or premixed within 90 days before screening; a history of an acute coronary or cerebrovascular event within 90 days before randomization; planned revascularization of a coronary, carotid, or peripheral artery; or long-term dialysis. (A complete list of exclusion criteria is provided in Table S2 in the Supplementary Appendix.)

PROCEDURES

The randomization of patients was stratified according to cardiovascular disease status (established cardiovascular or chronic kidney disease or cardiovascular risk factors only), insulin treatment (none, basal insulin only, or premixed insulin), and estimated glomerular filtration rate (≤ 30 ml or >30 ml per minute per 1.73 m² of body-surface area) at screening. A fixed dose-escalation procedure was used, with a starting dose of 0.25 mg for 4 weeks that escalated to 0.5 mg for 4 weeks until the maintenance dose (0.5 mg or 1.0 mg) was reached. No change in



A Quick Take is available at NEJM.org

the maintenance dose of either semaglutide or placebo was permitted during the treatment period.

Patients were scheduled for quarterly site visits during the trial. All investigators were encouraged to treat all the patients according to local guidelines to achieve the most effective glycemic control (Table S3 in the Supplementary Appendix), and additional noninvestigational antihyperglycemic medication (nonincretin-based therapy) could be added or adjusted.

OUTCOMES

The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction (including silent), or nonfatal stroke. Prespecified secondary outcomes included the first occurrence of an expanded composite cardiovascular outcome (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization [coronary or peripheral], and hospitalization for unstable angina or heart failure), an additional composite outcome (death from all causes, nonfatal myocardial infarction, or nonfatal stroke), the individual components of the composite outcomes, retinopathy complications, and new or worsening nephropathy. Each outcome, except for peripheral revascularization, was adjudicated in a blinded fashion by an external, independent event-adjudication committee.

Continuous efficacy and safety outcomes were assessed as the change from baseline to week 104. From baseline to week 109, we assessed serious and nonserious adverse events and hypoglycemic episodes, which were defined as severe (according to American Diabetes Association criteria⁶) or as confirmed on analysis of plasma glucose (with symptomatic hypoglycemia defined as <56 mg per deciliter [3.1 mmol per liter]). Neoplasm and pancreatitis events were adjudicated. (All definitions of adjudicated events are provided in Table S4 in the Supplementary Appendix.)

STATISTICAL ANALYSIS

The prespecified statistical analysis plan is available with the protocol at NEJM.org. We based the sample size for the trial on an assumed annual primary-event rate of 1.98% in each group, a dropout rate of less than 10.0%, a mean in-trial observation time of 2.1 years, and a true hazard

ratio of 1.00. We determined that the enrollment of 3260 patients would be required to determine the primary outcome in at least 122 patients and provide a power of 90% to reject a hazard ratio of at least 1.80 at the 0.05 level of significance.

The prespecified analysis for the primary outcome was a Cox proportional-hazards model, with pooled treatment (semaglutide vs. placebo) as a fixed factor, and categorized according to all possible combinations of stratification factors used for randomization. The primary hypothesis was for noninferiority for the primary outcome. Such noninferiority was confirmed if the upper boundary of the two-sided 95% confidence interval of the hazard ratio was below the noninferiority margin of 1.80.⁵ Testing for superiority for the primary outcome was not prespecified or adjusted for multiplicity. We conducted prespecified sensitivity analyses of the primary outcome, using alternative patient selection and data-censoring strategies for exposure to treatment, and per-protocol sensitivity analyses were performed post hoc. (Details regarding analysis sets are provided in the Supplementary Appendix.)

The primary outcome was evaluated in subgroups according to demographic and disease measures at baseline. We evaluated the effect of dose on the primary outcome by repeating the primary analysis with the four treatment groups (semaglutide doses of 0.5 mg and 1.0 mg and corresponding placebo doses) using volume-matched treatment comparisons. Efficacy and safety outcome analyses were prespecified to include the four treatment groups.

All P values are two-sided, with a level of 0.05 considered to indicate statistical significance. P values other than that for the primary hypothesis have not been adjusted for multiplicity and have been calculated to test for null hypotheses of no difference. All results were analyzed on an intention-to-treat basis that included the full analysis set (i.e., all patients who underwent randomization according to the planned treatment), with the exception of adverse events leading to premature discontinuation, which were included in the as-treated safety analysis.

RESULTS

PATIENTS

From February 2013 through December 2013, a total of 4346 patients were screened, and 3297

Table 1. Characteristics of the Patients at Baseline.*

| Characteristic | Semaglutide (N=1648) | | Placebo (N=1649) | | Total (N=3297) |
|--|-------------------------|-------------------|---------------------|-------------------|-------------------|
| | 0.5 mg (N=826) | 1.0 mg (N=822) | 0.5 mg (N=824) | 1.0 mg (N=825) | |
| Age — yr | 64.6±7.3 | 64.7±7.1 | 64.8±7.6 | 64.4±7.5 | 64.6±7.4 |
| Male sex — no. (%) | 495 (59.9) | 518 (63.0) | 482 (58.5) | 507 (61.5) | 2002 (60.7) |
| Body weight — kg | 91.8±20.3 | 92.9±21.1 | 91.8±20.3 | 91.9±20.8 | 92.1±20.6 |
| Type 2 diabetes | | | | | |
| Duration — yr | 14.3±8.2 | 14.1±8.2 | 14.0±8.5 | 13.2±7.4 | 13.9±8.1 |
| Glycated hemoglobin — % | 8.7±1.4 | 8.7±1.5 | 8.7±1.5 | 8.7±1.5 | 8.7±1.5 |
| Cardiovascular risk factors | | | | | |
| Systolic blood pressure — mm Hg | 136.1±18.0 | 135.8±17.0 | 135.8±16.2 | 134.8±17.5 | 135.6±17.2 |
| Diastolic blood pressure — mm Hg | 77.1±9.8 | 76.9±10.2 | 77.5±9.9 | 76.7±10.2 | 77.0±10.0 |
| Low-density lipoprotein cholesterol — mg/dl† | 81.6±47.1 | 83.3±41.2 | 80.9±48.1 | 83.6±45.9 | 82.3±45.6 |
| Never smoked — no. (%) | 390 (47.2) | 364 (44.3) | 391 (47.5) | 348 (42.2) | 1493 (45.3) |
| History of cardiovascular disease — no. (%) | | | | | |
| Ischemic heart disease | 493 (59.7) | 495 (60.2) | 510 (61.9) | 496 (60.1) | 1994 (60.5) |
| Myocardial infarction | 266 (32.2) | 264 (32.1) | 267 (32.4) | 275 (33.3) | 1072 (32.5) |
| Heart failure | 201 (24.3) | 180 (21.9) | 190 (23.1) | 206 (25.0) | 777 (23.6) |
| Ischemic stroke | 89 (10.8) | 89 (10.8) | 96 (11.7) | 109 (13.2) | 383 (11.6) |
| Hemorrhagic stroke | 28 (3.4) | 24 (2.9) | 27 (3.3) | 29 (3.5) | 108 (3.3) |
| Hypertension | 772 (93.5) | 771 (93.8) | 756 (91.7) | 760 (92.1) | 3059 (92.8) |

* Plus-minus values are means ±SD unless otherwise indicated. Differences in baseline characteristics were assessed with the use of analysis of covariance for continuous characteristics and logistic regression for categorical characteristics. There were no significant differences between the groups except for the duration of type 2 diabetes ($P=0.048$). To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.

† Values are geometric means and coefficients of variation.

underwent randomization; of these patients, 3232 (98.0%) attended the last follow-up visit at an investigator site, were contacted by telephone, or died during the trial. The date of the last patient visit was March 15, 2016. Vital status was known for 99.6% of the patients by the end of the trial (Figs. S1A and S1B in the Supplementary Appendix).

The median observation time was 2.1 years. Rates of premature treatment discontinuation were similar across groups (20% overall) (Table S5 in the Supplementary Appendix). The mean percentage of time during which patients received semaglutide was 86.5% (87.7% among those receiving 0.5 mg and 85.3% among those receiving 1.0 mg), and the mean percentage during which patients received placebo was 89.5% (89.4% among those receiving 0.5 mg and 89.6% among those receiving 1.0 mg).

Demographic and clinical characteristics of the patients at baseline were similar across treatment groups (Table 1, and Table S6 in the Supplementary Appendix). Of the 3297 patients, 2735 (83.0%) had established cardiovascular disease (including chronic kidney disease of stage 3 or higher), 1940 patients (58.8%) had established cardiovascular disease without chronic kidney disease, 353 (10.7%) had chronic kidney disease only, and 442 (13.4%) had both cardiovascular disease and kidney disease; 17% of the patients had cardiovascular risk factors and were 60 years of age or older. The overall mean duration of type 2 diabetes was 13.9 years, and the mean glycated hemoglobin level was 8.7%. The use of anti-hyperglycemic and cardiovascular medications was well balanced between the groups (Tables S7A and S8A in the Supplementary Appendix). Most patients (93.5%) were taking antihyperten-

sive medication, including angiotensin-converting–enzyme inhibitors (49.8%) and angiotensin-receptor blockers (33.7%); 76.5% were receiving lipid-lowering medications; and 76.3% were receiving antithrombotic medications, including acetylsalicylic acid (63.9%) and adenosine diphosphate receptor inhibitors (21.1%) (Table S8A in the Supplementary Appendix).

CARDIOVASCULAR OUTCOMES

The composite primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and 146 of 1649 (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95; $P < 0.001$ for noninferiority; $P = 0.02$ for superiority) (Fig. 1A). Sensitivity analyses supported the findings from the primary analysis (Fig. S2 in the Supplementary Appendix). Nonfatal myocardial infarction occurred in 47 patients (2.9%) in the semaglutide group and 64 (3.9%) in the placebo group, a difference that was not significant (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; $P = 0.12$) (Fig. 1B). Nonfatal stroke occurred in 27 patients (1.6%) in the semaglutide group and 44 (2.7%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; $P = 0.04$) (Fig. 1C). The risk of cardiovascular death was similar in the two groups, with deaths reported in 44 patients (2.7%) in the semaglutide group and 46 (2.8%) in the placebo group (hazard ratio, 0.98; 95% CI, 0.65 to 1.48; $P = 0.92$) (Fig. 1D).

No significant treatment interactions were identified for any subgroups (Fig. S3 in the Supplementary Appendix). Similar risk reductions for the primary outcome and its components were observed for both doses of semaglutide (Fig. S4 in the Supplementary Appendix). Cardiovascular outcomes are provided in Table 2, and in Table S9 in the Supplementary Appendix. Throughout the trial, a greater proportion of patients in the placebo group than in the semaglutide group received additional cardiovascular medications, including antihypertensive agents, diuretics, and lipid-lowering medications (Table S8B in the Supplementary Appendix).

GLYCEMIC CONTROL

At week 104, among patients receiving semaglutide, the mean glycated hemoglobin level decreased from 8.7% at baseline to 7.6% in the group receiving 0.5 mg and to 7.3% in the group receiving 1.0 mg, for changes of -1.1% and

-1.4% , respectively; in the placebo group, the mean level decreased to 8.3% in the two dose groups, for a reduction of 0.4% in each group. Thus, the mean glycated hemoglobin level in the semaglutide group, as compared with the placebo group, was 0.7 percentage points lower in the group receiving 0.5 mg and 1.0 percentage point lower in the group receiving 1.0 mg (estimated treatment difference) ($P < 0.001$ for both comparisons) (Fig. 2A, and Table S10 in the Supplementary Appendix). During the trial, significantly more patients in the placebo group than in the semaglutide group received additional antihyperglycemic agents, including insulin, which was initiated more than twice as frequently in the placebo group (Table S7B in the Supplementary Appendix).

BODY WEIGHT

At week 104, among patients receiving semaglutide, the mean body weight decreased from 92.1 kg at baseline to 88.5 kg in the group receiving 0.5 mg and to 87.2 kg in the group receiving 1.0 mg, for changes of -3.6 kg and -4.9 kg, respectively; in the placebo group, the mean body weight decreased to 91.4 kg and 91.6 kg, for changes of -0.7 kg and -0.5 kg, respectively. Thus, the mean body weight in the semaglutide group, as compared with the placebo group, was 2.9 kg lower in the group receiving 0.5 mg and 4.3 kg lower in the group receiving 1.0 mg ($P < 0.001$ for both comparisons) (Fig. 2B, and Table S10 in the Supplementary Appendix).

MICROVASCULAR OUTCOMES

Diabetic retinopathy complications occurred in 50 patients (3.0%) in the semaglutide group and 29 (1.8%) in the placebo group (hazard ratio, 1.76; 95% CI, 1.11 to 2.78; $P = 0.02$) (Table 2, and Table S9 and Fig. S5 in the Supplementary Appendix). The treatment difference between groups was first seen very early in the trial. The numbers of patients who required retinal photocoagulation were 38 (2.3%) in the semaglutide group versus 20 (1.2%) in the placebo group, the numbers of those who required the use of an intravitreal agent were 16 (1.0%) versus 13 (0.8%), the numbers of those who had a vitreous hemorrhage were 16 (1.0%) versus 7 (0.4%), and the numbers of those who had an onset of diabetes-related blindness were 5 (0.3%) versus 1 (0.1%) (Table S9 in the Supplementary Appendix). Of




Figure 1. Cardiovascular Outcomes.

Shown are Kaplan–Meier plots of the primary outcome (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) (Panel A), nonfatal myocardial infarction (Panel B), nonfatal stroke (Panel C), and death from cardiovascular causes (Panel D). The trial included a planned observation period of 109 weeks for all patients (a 104-week treatment period with a 5-week follow-up period). In Panel C, there were no events in the semaglutide group after week 104. Insets show the same data on an expanded y axis.

Table 2. Primary and Secondary Cardiovascular and Microvascular Outcomes.

| Outcome | Semaglutide (N=1648) | | Placebo (N=1649) | | Hazard Ratio (95% CI)* | P Value |
|---|-------------------------|----------------------|---------------------|----------------------|---------------------------|---|
| | no. (%) | no./100 person-yr | no. (%) | no./100 person-yr | | |
| Primary composite outcome† | 108 (6.6) | 3.24 | 146 (8.9) | 4.44 | 0.74 (0.58–0.95) | <0.001 for noninferiority; 0.02 for superiority |
| Expanded composite outcome‡ | 199 (12.1) | 6.17 | 264 (16.0) | 8.36 | 0.74 (0.62–0.89) | 0.002 |
| All-cause death, nonfatal myocardial infarction, or nonfatal stroke | 122 (7.4) | 3.66 | 158 (9.6) | 4.81 | 0.77 (0.61–0.97) | 0.03 |
| Death | | | | | | |
| From any cause | 62 (3.8) | 1.82 | 60 (3.6) | 1.76 | 1.05 (0.74–1.50) | 0.79 |
| From cardiovascular cause | 44 (2.7) | 1.29 | 46 (2.8) | 1.35 | 0.98 (0.65–1.48) | 0.92 |
| Nonfatal myocardial infarction | 47 (2.9) | 1.40 | 64 (3.9) | 1.92 | 0.74 (0.51–1.08) | 0.12 |
| Nonfatal stroke | 27 (1.6) | 0.80 | 44 (2.7) | 1.31 | 0.61 (0.38–0.99) | 0.04 |
| Hospitalization for unstable angina pectoris | 22 (1.3) | 0.65 | 27 (1.6) | 0.80 | 0.82 (0.47–1.44) | 0.49 |
| Revascularization | 83 (5.0) | 2.50 | 126 (7.6) | 3.85 | 0.65 (0.50–0.86) | 0.003 |
| Hospitalization for heart failure | 59 (3.6) | 1.76 | 54 (3.3) | 1.61 | 1.11 (0.77–1.61) | 0.57 |
| Retinopathy complications§ | 50 (3.0) | 1.49 | 29 (1.8) | 0.86 | 1.76 (1.11–2.78) | 0.02 |
| New or worsening nephropathy¶ | 62 (3.8) | 1.86 | 100 (6.1) | 3.06 | 0.64 (0.46–0.88) | 0.005 |

* Hazard ratios and P values were estimated with the use of a Cox proportional-hazards model with the study treatments as fixed factors and stratified according to all combinations of stratification factors used in the randomization.

† The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

‡ The expanded composite outcome included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization (coronary or peripheral), and hospitalization for unstable angina or heart failure.

§ Retinopathy complications include vitreous hemorrhage, onset of diabetes-related blindness, and the need for treatment with an intravitreal agent or retinal photocoagulation.

¶ New or worsening nephropathy includes persistent macroalbuminuria, persistent doubling of the serum creatinine level and a creatinine clearance of less than 45 ml per minute per 1.73 m² of body-surface area (according to the Modification of Diet in Renal Disease criteria), or the need for continuous renal-replacement therapy.

the 79 patients with retinopathy complications, 66 (83.5%) had preexisting retinopathy at baseline (42 of 50 [84.0%] in the semaglutide group and 24 of 29 [82.8%] in the placebo group). New or worsening nephropathy occurred in 62 patients (3.8%) in the semaglutide group and 100 (6.1%) in the placebo group (hazard ratio, 0.64; 95% CI, 0.46 to 0.88; $P=0.005$) (Table 2, and Table S9 and Fig. S5 in the Supplementary Appendix).

OTHER OUTCOMES

At week 104, among patients receiving semaglutide, the mean systolic blood pressure decreased from 135.6 mm Hg at baseline to 132.2 mm Hg among those receiving 0.5 mg and to 130.3 mm Hg

among those receiving 1.0 mg, for reductions of 3.4 mm Hg and 5.4 mm Hg, respectively; in the placebo group, the mean systolic blood pressure decreased to 133.5 mm Hg and 132.8 mm Hg, for reductions of 2.2 mm Hg and 2.8 mm Hg, respectively. Thus, the mean systolic blood pressure in the semaglutide group, as compared with the placebo group, was 1.3 mm Hg lower in the group receiving 0.5 mg ($P=0.10$) and 2.6 mm Hg lower in the group receiving 1.0 mg ($P<0.001$) (Table S10 and Fig. S6 in the Supplementary Appendix).


At week 104, among patients in the semaglutide group, the mean pulse rate increased from a baseline value of 72.0 bpm by 2.1 bpm among those receiving 0.5 mg and by 2.4 bpm among

those receiving 1.0 mg; in the placebo group, the corresponding changes were an increase of 0.1 bpm and a decrease of 0.1 bpm. Thus, the mean pulse rate in the semaglutide group, as compared with the placebo group, was 2.0 bpm higher in the group receiving 0.5 mg and 2.5 bpm higher in the group receiving 1.0 mg ($P < 0.001$ for both comparisons). Changes in diastolic blood pressure were similar in the treatment groups. Lipid measurements are provided in Table S10 in the Supplementary Appendix.

SAFETY

Gastrointestinal disorders were more frequent in the semaglutide group than in the placebo group (Table 3, and Table S11 in the Supplementary Appendix). The majority of gastrointestinal events were mild or moderate in severity and occurred during the first 30 weeks. Treatment discontinuation because of adverse events (mainly gastrointestinal) was more frequent in the semaglutide group than in the placebo group. The frequency and rate of serious adverse events, including serious cardiac disorders, were lower in the semaglutide group than in the placebo group (Table S11 in the Supplementary Appendix).

Acute pancreatitis occurred in 9 patients in the semaglutide group and in 12 in the placebo group; all events were mild, according to the revised Atlanta criteria.⁷ Lipase and amylase levels were significantly higher in the semaglutide group than in the placebo group (Fig. S7 in the Supplementary Appendix). Gallbladder disorders occurred in 58 patients in the semaglutide group and 61 in the placebo group. The rates of malignant neoplasms, which were similar in the two groups, were higher in the semaglutide group receiving 1.0 mg and lower in the group receiving 0.5 mg than in the placebo groups (Table 3, and Fig. S8 in the Supplementary Appendix). Pancreatic cancer occurred in 1 patient receiving 1.0 mg of semaglutide and in 4 patients receiving placebo. No medullary thyroid carcinomas were confirmed by the event-adjudication committee in either treatment group. Antibodies against semaglutide were detected in 30 patients treated with semaglutide, with the greatest number of patients (14) testing positive at week 44. In the majority of patients, antibody formation was transient — only 4 patients tested positive during follow-up — and antibody titers were generally low.



Similar numbers and occurrence rates of severe hypoglycemic episodes or hypoglycemia as confirmed on plasma glucose testing were seen with semaglutide doses of 0.5 mg and 1.0 mg (191 [23.1%] and 178 [21.7%], respectively), as compared with placebo doses of 0.5 and 1.0 mg (177 [21.5%] and 173 [21.0%]).

DISCUSSION

In this cardiovascular outcomes trial, we confirmed our primary hypothesis that semaglutide would be noninferior to placebo. Semaglutide-treated patients had a significant 26% lower risk of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than did those receiving

Table 3. Selected Adverse Events.*

| Event | Semaglutide | | Placebo | |
|--|-------------------------------------|-------------------|-------------------|-------------------|
| | 0.5 mg (N=826) | 1.0 mg (N=822) | 0.5 mg (N=824) | 1.0 mg (N=825) |
| | <i>number of patients (percent)</i> | | | |
| Adverse event | 740 (89.6) | 732 (89.1) | 748 (90.8) | 736 (89.2) |
| Serious adverse event† | 289 (35.0) | 276 (33.6) | 329 (39.9) | 298 (36.1) |
| Severe adverse event‡ | 200 (24.2) | 207 (25.2) | 216 (26.2) | 194 (23.5) |
| Adverse event leading to treatment discontinuation | 95 (11.5) | 119 (14.5) | 47 (5.7) | 63 (7.6) |
| Nausea | 18 (2.2) | 38 (4.6) | 2 (0.2) | 2 (0.2) |
| Vomiting | 14 (1.7) | 23 (2.8) | 3 (0.4) | 2 (0.2) |
| Diarrhea | 15 (1.8) | 19 (2.3) | 5 (0.6) | 2 (0.2) |
| Gastrointestinal disorder§ | 419 (50.7) | 430 (52.3) | 294 (35.7) | 290 (35.2) |
| Diarrhea | 148 (17.9) | 151 (18.4) | 98 (11.9) | 87 (10.5) |
| Nausea | 143 (17.3) | 180 (21.9) | 62 (7.5) | 67 (8.1) |
| Vomiting | 87 (10.5) | 122 (14.8) | 43 (5.2) | 34 (4.1) |
| Cardiac disorder§ | 173 (20.9) | 150 (18.2) | 189 (22.9) | 173 (21.0) |
| Atrial fibrillation | 27 (3.3) | 23 (2.8) | 32 (3.9) | 26 (3.2) |
| Acute pancreatitis¶ | 6 (0.7) | 3 (0.4) | 3 (0.4) | 9 (1.1) |
| Gallbladder disorder | 32 (3.9) | 26 (3.2) | 38 (4.6) | 23 (2.8) |
| Cholelithiasis | 21 (2.5) | 17 (2.1) | 19 (2.3) | 12 (1.5) |
| Acute cholecystitis | 4 (0.5) | 0 | 6 (0.7) | 2 (0.2) |
| Severe or symptomatic hypoglycemic event** | 191 (23.1) | 178 (21.7) | 177 (21.5) | 173 (21.0) |
| Acute renal failure | 42 (5.1) | 23 (2.8) | 34 (4.1) | 35 (4.2) |
| Allergic reaction | 49 (5.9) | 49 (6.0) | 46 (5.6) | 57 (6.9) |
| Injection-site reaction | 8 (1.0) | 9 (1.1) | 9 (1.1) | 12 (1.5) |
| Neoplasm¶ | 66 (8.0) | 89 (10.8) | 70 (8.5) | 69 (8.4) |
| Benign | 40 (4.8) | 54 (6.6) | 36 (4.4) | 34 (4.1) |
| Premalignant | 4 (0.5) | 6 (0.7) | 3 (0.4) | 2 (0.2) |
| Malignant | | | | |
| Any | 26 (3.1) | 40 (4.9) | 35 (4.2) | 35 (4.2) |
| Pancreatic | 0 | 1 (0.1) | 2 (0.2) | 2 (0.2) |

* Adverse events were selected on the basis of the safety areas of interest for GLP-1-receptor agonists. All data are based on investigator-reported adverse events unless otherwise specified. All data were reported during the trial, except for adverse events leading to treatment discontinuation, which are reported on an as-treated basis. A complete list of serious adverse events according to system organ class is provided in Table S10 in the Supplementary Appendix.

† A serious adverse event was defined as death, a life-threatening episode, hospitalization or prolongation of existing hospitalization, a persistent or substantial disability or incapacity, or an event otherwise considered to be an important medical event.

‡ A severe adverse event was defined as an event that considerably interferes with the patient's daily activities and is unacceptable.

§ This category was defined according to the system organ class in the *Medical Dictionary for Regulatory Activities* (MedDRA).

¶ This event was confirmed by the event-adjudication committee.

|| This category was based on the group of preferred terms in MedDRA.

** This category of hypoglycemic event includes episodes of severe hypoglycemia (defined according to the American Diabetes Association criteria) or symptomatic hypoglycemia as confirmed on plasma glucose testing (<56 mg per deciliter [3.1 mmol per liter]).

placebo. This lower risk was principally driven by a significant (39%) decrease in the rate of nonfatal stroke and a nonsignificant (26%) decrease in nonfatal myocardial infarction, with no significant difference in the rate of cardiovascular death. Similar risk reductions were observed with both doses of semaglutide. The number of patients who would need to be treated to prevent one event of the primary outcome over a period of 24 months was 45 on the basis of Kaplan-Meier estimates.⁸ Most study patients were receiving cardiovascular risk management at baseline, as shown by a high proportion of patients receiving antihypertensive, lipid-lowering, and anti-platelet medications. The risk reduction for the primary outcome was seen despite an increase in pulse rate, a class effect for GLP-1-receptor agonists.

Semaglutide-treated patients had a lower risk of new or worsening nephropathy, according to differences in macroalbuminuria, but a higher risk of diabetic retinopathy complications than did those receiving placebo. Although the overall number of retinopathy events was low, there was an unexpected higher rate of retinopathy complications (vitreous hemorrhage, blindness, or the need for treatment with an intravitreal agent or photocoagulation) in the semaglutide group. An association between rapid glucose lowering and worsening of retinopathy has been reported in patients with type 1 diabetes.^{9,10} The applicability of such an association to our finding is unclear, and a direct effect of semaglutide cannot be ruled out.

Semaglutide was associated with significant and sustained reductions in glycated hemoglobin levels, as compared with placebo, with similar rates of hypoglycemia. During the trial, more patients in the placebo group than in the semaglutide group intensified their antihyperglycemic treatment. However, the between-group difference in glycated hemoglobin levels remained after 2 years. Clinically meaningful and sustained weight loss and a reduction in systolic blood pressure occurred in the semaglutide group versus the placebo group over 2 years. The reductions in glycated hemoglobin, body weight, and systolic blood pressure may all have contributed to the observed reduction in cardiovascular risk with semaglutide.

With the exception of complications of reti-

nopathy, semaglutide had a safety profile similar to that of other GLP-1-receptor agonists. The rate of malignant neoplasms was similar in the pooled semaglutide group and the pooled placebo group, although the highest rate was observed with the semaglutide dose of 1.0 mg. The rate of pancreatic cancer — an event of interest for this drug class — was lower with semaglutide, and no medullary thyroid carcinomas were reported in this trial. Pancreatitis occurred in low yet similar numbers of patients in the two pooled groups.

To date, two antihyperglycemic agents have been shown to reduce the rate of cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.^{2,3} In this trial, the risk reduction of the primary outcome was driven by a significant decrease in the rate of nonfatal stroke and a nonsignificant decrease in the rate of nonfatal myocardial infarction, with no difference in cardiovascular death. The beneficial effect of semaglutide on cardiovascular outcomes may relate to modification of the progression of atherosclerosis.

This trial was powered as a noninferiority study to exclude a preapproval safety margin of 1.8 set by the Food and Drug Administration. It was not powered to show superiority, so such testing was not prespecified. However, the treatment effect of semaglutide and the accrual of more events than estimated resulted in a significantly lower risk of the primary outcome among patients in the semaglutide group. Patients were followed for a relatively short duration (2.1 years) and were at high cardiovascular risk. The generalizability of these findings to other populations and a longer duration of treatment is unknown. It is also unknown to what extent the greater glycated hemoglobin reductions in the semaglutide group contributed to the results.

In conclusion, among patients with type 2 diabetes at high cardiovascular risk, the rate of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke was significantly lower in those receiving semaglutide than in those receiving placebo, which confirmed noninferiority.

Supported by Novo Nordisk.

Dr. Marso reports receiving fees for physician education from Abbott Vascular, consulting fees from Novo Nordisk and AstraZeneca, and grant support to his institution from Novo Nordisk; Dr. Bain, receiving consulting fees from Novo Nordisk, Eli Lilly,

Boehringer Ingelheim, AstraZeneca, Sanofi Aventis, and Merck Sharp & Dohme, and grant support from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi Aventis, Merck Sharp & Dohme, GenMedica, and CeQur; Dr. Consoli, receiving lecture fees and fees for serving on advisory boards from Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi Aventis, Merck Sharp & Dohme, and Takeda and grant support to his institution from Novo Nordisk; Dr. Eliaschewitz, receiving lecture fees and fees for serving on advisory boards from Novo Nordisk, Sanofi Aventis, AstraZeneca, Merck Sharp & Dohme, Takeda, Boehringer Ingelheim, and Eli Lilly; Dr. Jódar, receiving consulting and lecture fees and fees for serving as a clinical investigator from Eli Lilly, Novo Nordisk, GlaxoSmithKline, Janssen, AstraZeneca, and Merck; Dr. Leiter, receiving fees for serving on advisory boards from Aegerion, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, and Servier, fees for providing continuing medical education on behalf of Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi, and grant support to his institution from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Pfizer, Sanofi, Servier, and the Medicines Company; Dr. Lingvay, receiving writing assistance from Novo Nordisk, Boehringer Ingelheim, and Sanofi and grant support to her institution from Novo Nordisk, Merck, Pfizer, and GI Dynamics; Dr. Rosenstock, receiving grant support from Novo Nordisk; Dr. Seufert, receiving lecture fees and fees for serving on advisory boards from Sanofi, Boehringer Ingelheim, AstraZeneca, and Janssen and

grant support from Boehringer Ingelheim and that his institution has served as a trial and recruitment center for trials sponsored by Janssen and Intarcia; Dr. Warren, receiving fees for serving on advisory boards from Novo Nordisk and Eli Lilly, lecture fees from Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, and Merck, travel support from Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi, and grant support to his institution from Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Sanofi, Medtronic, Mylan Pharmaceuticals, MannKind, and Janssen; Dr. Woo, receiving lecture fees, fees for serving on advisory boards, and grant support from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Sanofi; Mr. Hansen, Dr. Holst, and Dr. Pettersson, being employees of Novo Nordisk; and Dr. Vilsbøll, receiving consulting fees and fees for serving on advisory boards from Amgen, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck Sharp & Dohme, Sanofi, Takeda, and Novo Nordisk and grant support from Eli Lilly and Novo Nordisk. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank all the patients, investigators, and trial-site staff members who were involved in the conduct of the trial; Eirik Quamme Bergan, M.D., and Lars Holm Damgaard, Ph.D. (both from Novo Nordisk), for their review and suggestions for revising the manuscript; and Katrina de Saram, Ph.D., and Madeleine Nowak, M.Sci. (both from AXON Communications), for medical writing and editorial assistance.

REFERENCES

1. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. *Int J Hypertens* 2013;2013:653789.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117-28.
3. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;375:311-22.
4. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. *J Med Chem* 2015;58:7370-80.
5. Food and Drug Administration. Guidance for industry: Diabetes mellitus — evaluating cardiovascular risk in new anti-diabetic therapies to treat type 2 diabetes. December 2008 (<http://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm071627.pdf>).
6. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care* 2013;36:1384-95.
7. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis — 2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62:102-11.
8. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. *BMJ* 1999;319:1492-5.
9. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. *Arch Ophthalmol* 1998;116:874-86.
10. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. *Br Med J (Clin Res Ed)* 1985;290:811-5.

Copyright © 2016 Massachusetts Medical Society.

TRACK THIS ARTICLE'S IMPACT AND REACH

Visit the article page at NEJM.org and click on the Metrics tab for a dashboard that logs views, citations, media references, and commentary, with easy linking. Learn more at www.nejm.org/page/article-metrics-faq.